Gyg Share Discussion Threads

[pkw] 04/9/2003 11:25

orvis - agree that lid must come off soon - I see GYG getting
back to the old £4.00 level.

(did anyone else have a look at AMS? - convinced they will prove
to be a major winner)

[orvis] 03/9/2003 23:12

Nearly all buys today. 1 MM had to buy stock too. Lid has to come off soon IMO.

[orvis] 02/9/2003 17:05

MM's have to run out of stock eventually! They are soaking up continuous buys and only marked up bid a penny over 2 days.
This one was tipped in the Sunday Times this weekend as an institutional favourite buy - just like the Citywire comment posted above.

[cockneyrebel] 01/9/2003 20:38

Well doing research tonight on GYG and found this on Citywire from today - might interest holders. You need to be a Citywire subscriber.

Star fund manager Nigel Thomas has taken his place along side several other shrewd investors with holdings in Gyrus Group ahead of the £200 million medical devices company's interim results.

[cockneyrebel] 01/9/2003 16:01

cheers, just rooting around at the moment - might have to have a few before the results as a trade perhaps - looks promising.

CR

[cockneyrebel] 01/9/2003 15:11

Loads of buys in this today - are there good things expected at the results in a week or so?

Not followed this very closely I'm affraid - feeling lazy today :-)

CR

[ok,yah] 22/8/2003 23:33

Gyrus Group plc (LSE: GYG), the medical device company, will announce its
interim results for the six months ended 30 June 2003 on Tuesday, 9 September
2003.

[ok,yah] 21/8/2003 00:55

This must be about to enter the FTSE250 as well which is likely to provide a stimulus.

[gzr] 20/8/2003 00:37

Yep, came out 4th Sep last year.

[matthewa] 20/8/2003 00:13

GZR - Something like that. Reckon results will be well tasty.

[gzr] 19/8/2003 11:39

Breaking out strongly now, no resistance until 300p?

[matthewa] 13/8/2003 00:55

Close to Breaking out of it recent range

[ok,yah] 11/8/2003 11:05

seems like we can! Decent buying this am

[ok,yah] 11/8/2003 09:11

Gyrus group seems to have broker support;

Four brokers rate them a strong buy, three brokers a buy and just one a hold.

With interims due in September and the latest trading update very bullish saying that they will exceed consensus forecasts AND accelerated growth is likely in H2, can we expect a decent run up in price I wonder?

[qazwsx123] 08/8/2003 09:44

8 August 2003,
Alizyme (AZM):

Superb announcement from Alizyme today regarding out-licensing deal with Takeda, the largest pharmaceutical company in Japan, for Japanese rights to ATL-962 for the treatment of obesity and all related diseases.

* Exclusive rights for Japan.

* Total agreement worth up to US$42 million:
..........US$2 million payable immediately
..........US$40 million payable on future milestones/events
..........US $42 total (i.e. between now and ATL-962 reaching the market)

* Double digit royalties on future sales by Takeda in Japan.

* All development costs in Japan paid by Takeda.

[maddox] 12/7/2003 12:06

Wow, nice to have company on this BB.

What the trading statement mentions but doesn't major on is that they have just tied up a new product in the Otology (hearing) market with a potential $1.4bn target market. And this in a niche sector where they are the dominant player with 54% market share.

This is yet another string to their bow.

Regards, Maddox

[pkw] 09/7/2003 14:50

Back in, after a gap of about 3 years with this one! Always liked the company
but felt it needed to make its mark more - well, today's statement is about
as positive as you can get and is putting up a big BUY banner for all to read!

I will be delighted if GYG now justifies its potential - and gets back
to the old £4.00 level!

(And for those who like companies in this field - don't miss AMS: looks
as though it is about to take off in a major way)

[parvez] 09/7/2003 07:20

>>>>Dr DarkStar - you may well be right !!! Trading statement today seems exciting>>>>>>>>>>>>

Embargoed for Release, 9th July - 7.00a.m. (BST)


GYRUS PRE-CLOSE PERIOD TRADING UPDATE

TRADING AHEAD OF CONSENSUS FORECASTS WITH ACCELERATING GROWTH EXPECTED IN THE
SECOND HALF OF THE YEAR

READING, UK - Gyrus Group PLC, (GYG.L "Gyrus" or "the Group") a leading supplier
of medical devices to reduce trauma and complications in surgery, today
announces a trading update prior to the start of the close period.

Revenue for the six months ended 30 June 2003 will be in the range #37 - #37.5
million which includes a 10% translation impact caused by the continued weakness
of the US dollar.

Direct sales, which exclude sales to corporate partners, grew 14% at a constant
exchange rate. Growth accelerated in the second quarter following the
reorganisation implemented at the beginning of the year.

EBITA is expected to exceed 10% of revenue in the first half (H1 2002: 8%)
combined with strong cash generation.

About 55% of 2003 revenue is expected to come in the second half driven by a
combination of new product introductions, continued upgrading of our US sales
force and expansion in selected European markets. More specifically, Gyrus
expects the following factors to stimulate higher levels of growth in the second
half of the year:

* Increasing adoption of the PK Open Forceps in Gynaecology, Urology and
General Surgery as volume manufacturing comes on stream.
* Introduction of the new high performance PK SuperPulse platform in Q3,
building on the 37% growth (H1 2003:H1 2002) in urology seen in the first
half.
* Expanding the Diego microdebrider product line to exceed the 75% growth
(H1 2003:H1 2002) seen in the Sinus and Rhinology Business Unit in the first
half.
* Leveraging the Group's market dominance in otology to rapidly grow sales
in the $1.4 billion US market for the revolutionary RetroX hearing
enhancement system.
* The VAPR 3 Arthroscopic system significantly contributing to a return to
high single-digit growth for the corporate partner businesses with J&J,
Guidant and Bard.
* Expanding in Europe with a direct selling model in selected territories to
mirror the UK operation which grew the branded business 25% (H1 2003:H1
2002) in the first half.

Brian Steer, Chairman, Gyrus Group PLC, said: "We continue to reposition the
Group to take advantage of our strengths in technology, sales and distribution.
We are demonstrating the ability to drive revenue in our direct business,
control costs, generate cash and increase profitability, giving us an excellent
platform on which to accelerate our growth to the high teens rate to which we
are committed."

[dr darkstar] 08/6/2003 22:12

Very heavy volume on the up move 2 days ago off support from the previously broken downtrend line suggests the next move could reach 300 DYOR

[divina] 03/6/2003 07:28

A good looking agreement today

Gyrus already do trade of $22m in otology
this could easily double

[onlyonestorm] 13/5/2003 13:41

Bainsey

Any logical reason for this statement or did you throw a dart at the FT?

STORMY

PS - I HOPE YOUR CORRECT!!!!!!!!!

[maddox] 05/3/2003 23:27

Mathewa,

Your obviously shorting then - hence the misinformation. Gyrus is not a Biotech and has just reported its maiden bottom-line profit.

The profit is flattered by a profit on disposal, but a profit is a profit, and the figures were hit by dollar translation. Nevertheless, the management are targeting high-teen annual revenues growth and continuing widening margins - and they have always delivered.

As Gyrus is increasing its target markets, most of which are growing, there is every likelihood that this high growth can be sustained over a long period. This will drive the share price forward whether or not growth stocks come back into fashion.

Maddox